Dissolution of the French subsidiary conducting OTSA101 clinical trials
First written in FY2020-Q1. 1 of 2 entries say "Achieved", first in FY2020-Q2. Latest entry: FY2020-Q2.
The whole theme swung hardest in 2024: 2 of 11 companies on the "Worse" side.
35 other companies' latest entry also says "Achieved".
- FY2020-Q2AchievedAnnual report
「Laboratoires OncoTherapy Science France S.A.R.L. resolved to dissolve at the Company's Board of Directors meeting on 24 April 2019, and liquidation was completed by 30 September of the same year.」
Following the completion of the procedures related to the Phase I clinical trial of OTSA101 in France, dissolution and liquidation of the subsidiary established to conduct the trial were completed. - FY2020-Q1First statedAnnual report
「Following the completion of the series of procedures associated with the Phase I clinical trial of OTSA101 in France, including the collection of related data, the Company resolved at its Board of Directors meeting on 24 April 2019 to dissolve Laboratoires OncoTherapy Science France S.A.R.L., a consolidated subsidiary established to conduct the trial.」
Following the completion of the Phase I clinical trial of OTSA101 in France and related procedures, the Board of Directors resolved to dissolve the consolidated subsidiary established to conduct the trial.